Healthpoint Biotherapeutics Introduces Copay Assistance Program For Collagenase Santyl Ointment

Fri Feb 1, 2013 9:32am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

FORT WORTH, Texas,  Feb. 1, 2013  /PRNewswire/ -- Healthpoint Biotherapeutics, a
Smith & Nephew business  (LSE: SN, NYSE: SNN), today announced the introduction
of a Copay Assistance Program for patients who have been prescribed Collagenase
SANTYL®  Ointment and pay more than  $50  out-of-pocket for their prescription.
Under the program, eligible patients cover the first  $50  and Healthpoint will
pay up to the next  $150  of out-of-pocket costs per prescription. The card can
be used for as many as six prescriptions at a retail pharmacy, up to a  $900 
annual maximum.

"We recognize that healthcare costs are an important consideration today and
some patients face difficult choices that could lead them to go without the
medicines they need," commented  Travis Baugh, President of Healthpoint
Biotherapeutics. "That is why we are so pleased to introduce the SANTYL® 
Ointment Copay Assistance Program as one means of ensuring patient access to
this important therapeutic option for managing often debilitating chronic

Both insured and uninsured patients may qualify for the Copay Assistance
Program, except for prescriptions reimbursed under governmental healthcare
programs or where otherwise restricted by law.  

Additional information, along with program terms and conditions, are available
online at  or by calling 1-800-364-4767.

About Collagenase SANTYL®  Ointment

Collagenase SANTYL®  Ointment is a selective enzymatic debriding agent that
provides continuous, bioactive removal of necrotic (dead) collagen without
harming granulation tissue (collagen-rich tissue which forms in the healing
wound). In difficult-to-heal and chronic wounds (such as diabetic, venous and
pressure ulcers), there is an ongoing deposition of non-viable tissue that must
be continually removed to maintain the readiness of the wound for healing. The
process of removing these barriers to healing is called debridement, which can
be accomplished through the use of certain enzymes (types of proteins) to
liquefy necrotic tissue, thus allowing bioburden (microorganisms contaminating
the wound) to be more easily removed from the wound.  

Ongoing, active removal of necrotic debris at the cellular level may help wounds
progress from the inflammatory phase (defense against infection) to the
proliferative phase (spreading of new cells over the wound bed) of healing. By
breaking the cycle of inflammation which traps many chronic wounds, SANTYL® 
Ointment contributes to the formation of granulation tissue and subsequent
epithelialization (regeneration of the epidermis across a wound surface).  

Collagenase SANTYL®  Ointment is the only product approved by the FDA for use as
an enzymatic debriding agent and is indicated for debriding chronic dermal
ulcers (e.g., pressure ulcers, venous ulcers and diabetic ulcers) and severely
burned areas. SANTYL®  Ointment contains 250 collagenase units per gram of white
petrolatum USP; the enzyme collagenase is derived from the fermentation by 
Clostridium histolyticum. Occasional slight transient erythema has been noted in
surrounding tissue when applied outside the wound. One case of systemic
hypersensitivity has been reported after one year of treatment with collagenase
and cortisone. For more information, please visit

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a bioactive business of Smith & Nephew focused on
the development and commercialization of novel, cost-effective solutions for
dermal repair and regeneration. Its research and development strategy is
centered around next-generation bioactive therapies for the treatment of chronic
wounds. Currently marketed products include Collagenase SANTYL®  Ointment,
OASIS®  Wound Matrix, OASIS®  Ultra Tri-Layer Matrix and REGRANEX® 
(becaplermin) Gel 0.01%. Healthpoint Biotherapeutics is also committed to
advancing the care and treatment of wounds through support of industry leading
continuing education from The Wound Institute®. To learn more about this
comprehensive and award winning educational resource, please visit®.  Healthpoint Biotherapeutics is a business of Smith &
Nephew (LSE: SN, NYSE: SNN), and is based in  Fort Worth, Texas. For more
information, visit the company website at

and REGRANEX are registered trademarks of Smith & Nephew.

OASIS is a registered trademark of Cook Biotech, Inc.

About Smith & Nephew  

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost
11,000 employees and a presence in more than 90 countries. Annual sales in 2011
were nearly  $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN,

SOURCE  Healthpoint Biotherapeutics, a Business of Smith & Nephew

Robert Bancroft, Executive Vice President, Strategic and Commercial Development,, +1-800-441-8227

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.